V&V Is a Lever, Not a Gate

The teams delivering the most roadmap are the ones that think about verification differently

Ask a medtech leadership team why the roadmap is behind and you will hear about headcount, scope creep, and regulatory surprises. You will rarely hear about verification and validation, because V&V is not usually thought of as something that determines delivery speed. It is thought of as something that happens near the end, after the real work.

That assumption is expensive, and it is why a lot of programs run slower than they need to.

Why V&V ends up late

It is worth being fair about how this happens, because it is almost never carelessness.

There is a milestone date that has to be hit, and design work is what moves the date. The V&V team is committed to another program and cannot engage when you would want them to. Budget is finite, and verification looks like a back-end activity, so it gets scheduled where the money is. And there is usually a quiet confidence that the development work so far is solid, which makes early verification feel redundant.

Every one of those is a reasonable pressure. Together, they push V&V to the end of the program almost every time.

What happens when it lands there

Problems do not wait until it is convenient to find them. They are created during design and development, and they sit there until somebody looks.

So when verification finally runs, issues surface at the worst possible moment. Most of the development is complete. The decisions that caused the problem are months old. And the engineers who made those decisions have often moved on to other programs. Now you are pulling people back, rebuilding context that has gone cold, and reworking choices that were easy to change six months ago and are not easy now.

That is where the schedule actually veers off the rails. Not into the testing itself but into the rework that testing uncovers too late to absorb.

Catching the same issue while the team is still building is an entirely different conversation. Same problem, a fraction of the disruption.

V&V as a capability, not an activity

The shift worth making is to stop treating V&V as something you schedule and start treating it as a key capability that you build.

That takes real investment: experienced V&V people, capacity that is available when programs need it rather than when it happens to free up, and engagement that starts at requirements rather than at test execution. When V&V is in the room during design reviews, requirements get written so they can be verified, and the hard questions get asked while the answers are still inexpensive.

The return shows up where leadership actually feels it, in development time, in delivery reliability, and in programs that land when you said they would.

Three moves

Bring V&V into requirements and design reviews, not just test execution. The value is in what gets prevented, not in what gets caught.

Staff V&V ahead of demand rather than on request. Availability is the constraint that quietly sets your schedule.

Fund V&V as a standing capability rather than a line item on each program. Capabilities compound across programs. Line items do not.

The point

None of this is an argument for testing more. It is an argument for engaging testing earlier, with people experienced enough to know what to ask.

V&V is not the tollbooth at the end of development. It is one of the few levers that lets a team deliver more of its roadmap with the people it already has. Most organizations have simply never treated it that way.

Suntra MedTech Solutions provides V&V capacity and the discipline behind it, inside FDA Class II and III programs. Let’s talk about where your programs are losing time. Visit SuntraMedTech.com/contact.